← Leaderboards
Joshua D Lee
New York University School Of Medicine
$16,892,346
Attributed
$38,832,231
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $21.2M · FY2008–25$25M$18.8M$12.5M$6.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$38,832,231 · 8
By mechanism
U01$26,633,982 · 3
R01$10,424,245 · 3
UM1$1,418,065 · 1
R25$355,939 · 1
Top collaborators
- Sungwoo Lim5 shared
- Ross Macdonald5 shared
- Jan Gryczynski3 shared
- Lisa A Marsch3 shared
- Sandra Ann Springer3 shared
- David J Farabee2 shared
- Elizabeth Needham Waddell2 shared
- David M Charytan1 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Katerina Heran Darwin$14,575,170
- Henry H Ruiz$722,270
- Ross Macdonald$1,035,502
- Sungwoo Lim$1,035,502
- John P Rotrosen$35,649,271
Others in their field
Top investigators on “Naltrexone”
- Edward V Nunes · Columbia University Health Sciences$84,879,719
- Marco Pravetoni · Hennepin Healthcare Research Institute$33,709,846
- John P Rotrosen · New York University School Of Medicine$27,496,918
- Charles P France · University Of Texas Hlth Science Center$21,946,147
- Louisa Gilbert · Columbia Univ New York Morningside$19,125,052
- Nabila El-Bassel · Columbia Univ New York Morningside$19,125,052
Research focus
NaltrexonePharmaceutical PreparationsMedicalPersonsCommunitiesCostOpioidAdultParticipantRandomizedImprisonmentEffectivenessEvaluationHeroinMethadoneClinical TrialsBaseAddictionCaringFda ApprovedInjectableNew York CityJailPrimary Outcome
Grant awards (27)
âGLP-1 Outcomes with people Using Psychoactive Substances (GLOW-UPS): a multi-stage, multi-site trial among persons involved in the criminal-legal system$1,418,065
UM1 · FY2025 · DA · contact PI
Substance Abuse Research Education and Training (SARET)$355,939
R25 · FY2025 · DA · contact PI
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults$2,498,125
U01 · FY2024 · DA · contact PI
Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017$636,299
R01 · FY2022 · DA · contact PI
Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017$612,389
R01 · FY2021 · DA · contact PI
Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017$596,192
R01 · FY2020 · DA · contact PI
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults$17,761,674
U01 · FY2019 · DA · contact PI
Pain, Opioids, and ESRD risk reduction with Mindfulness and Buprenorphine (POEM-B): A 3-arm multi-site randomized trial in hemodialysis patients$2,883,251
U01 · FY2019 · DK
Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017$594,838
R01 · FY2019 · DA · contact PI
Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017$666,787
R01 · FY2018 · DA · contact PI
Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-entry$305,100
U01 · FY2018 · DA · contact PI
Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care$675,515
R01 · FY2017 · AA · contact PI
Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-entry$528,379
U01 · FY2017 · DA · contact PI
Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care$1,016,741
R01 · FY2016 · AA · contact PI
Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-entry$677,777
U01 · FY2016 · DA · contact PI
Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care$1,346,636
R01 · FY2015 · AA · contact PI
Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-entry$672,308
U01 · FY2015 · DA · contact PI
Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care$1,300,572
R01 · FY2014 · AA · contact PI
Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-entry$678,642
U01 · FY2014 · DA · contact PI
Treatment Study Using Depot Naltrexone (3/6) NY/Bellevue Protocol Treatment Site$192,351
R01 · FY2014 · DA · contact PI
Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care$946,244
R01 · FY2013 · AA · contact PI
Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-entry$628,726
U01 · FY2013 · DA · contact PI
Treatment Study Using Depot Naltrexone(3/6)NY/Bellevue Protocol Treatment Site$351,586
R01 · FY2013 · DA · contact PI
Treatment Study Using Depot Naltrexone(3/6)NY/Bellevue Protocol Treatment Site$366,235
R01 · FY2012 · DA · contact PI
Treatment Study Using Depot Naltrexone(3/6)NY/Bellevue Protocol Treatment Site$366,235
R01 · FY2011 · DA · contact PI
Treatment Study Using Depot Naltrexone(3/6)NY/Bellevue Protocol Treatment Site$377,561
R01 · FY2010 · DA · contact PI
Treatment Study Using Depot Naltrexone(3/6)NY/Bellevue Protocol Treatment Site$378,064
R01 · FY2008 · DA · contact PI